Literature DB >> 1725918

31P spectroscopy of the human prostate gland in vivo using a transrectal probe.

J Kurhanewicz1, A Thomas, P Jajodia, M W Weiner, T L James, D B Vigneron, P Narayan.   

Abstract

Using a transrectal probe, good quality 31P magnetic resonance spectroscopy of the human prostate was performed safely, consistently, and in a reasonable amount of time (average of 60 min). Initial results indicate that transrectal 31P MRS has the ability to characterize the phosphorylated metabolites of normal, hyperplastic, and malignant prostates. This study demonstrated that malignant prostates are characterized by significantly decreased levels of phosphocreatine (PCr) and increased levels of phosphomonoesters (PME) as compared to healthy prostates.

Entities:  

Mesh:

Year:  1991        PMID: 1725918     DOI: 10.1002/mrm.1910220248

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  11 in total

1.  Two-dimensional MR spectroscopy of healthy and cancerous prostates in vivo.

Authors:  M Albert Thomas; Thomas Lange; S Sendhil Velan; Rajakumar Nagarajan; Steve Raman; Ana Gomez; Daniel Margolis; Stephany Swart; Raymond R Raylman; Rolf F Schulte; Peter Boesiger
Journal:  MAGMA       Date:  2008-07-17       Impact factor: 2.310

2.  Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2005

Review 3.  Citrate in the diagnosis of prostate cancer.

Authors:  L C Costello; R B Franklin; P Narayan
Journal:  Prostate       Date:  1999-02-15       Impact factor: 4.104

4.  Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor.

Authors:  Kayvan R Keshari; Renuka Sriram; Mark Van Criekinge; David M Wilson; Zhen J Wang; Daniel B Vigneron; Donna M Peehl; John Kurhanewicz
Journal:  Prostate       Date:  2013-03-26       Impact factor: 4.104

5.  Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy.

Authors:  Mark G Swanson; Kayvan R Keshari; Z Laura Tabatabai; Jeffry P Simko; Katsuto Shinohara; Peter R Carroll; Andrew S Zektzer; John Kurhanewicz
Journal:  Magn Reson Med       Date:  2008-07       Impact factor: 4.668

6.  Proton magnetic resonance spectroscopy with a body coil in the diagnosis of carcinoma prostate.

Authors:  Rajeev Kumar; Mahesh Kumar; N R Jagannathan; Narmada P Gupta; Ashok K Hemal
Journal:  Urol Res       Date:  2003-10-08

7.  A feasibility study of novel ultrasonic tissue characterization for prostate-cancer diagnosis: 2D spectrum analysis of in vivo data with histology as gold standard.

Authors:  Tian Liu; Mahesh M Mansukhani; Mitchell C Benson; Ronald Ennis; Emi Yoshida; Peter B Schiff; Pengpeng Zhang; Jun Zhou; Gerald J Kutcher
Journal:  Med Phys       Date:  2009-08       Impact factor: 4.071

Review 8.  Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer.

Authors:  Aleksandra Zapotoczna; Giuseppe Sasso; John Simpson; Mack Roach
Journal:  Neoplasia       Date:  2007-06       Impact factor: 5.715

9.  MR Spectroscopic Imaging of Peripheral Zone in Prostate Cancer Using a 3T MRI Scanner: Endorectal versus External Phased Array Coils.

Authors:  Rajakumar Nagarajan; Daniel Ja Margolis; Steven S Raman; David Ouellette; Manoj K Sarma; Robert E Reiter; M Albert Thomas
Journal:  Magn Reson Insights       Date:  2013-05-15

10.  Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics.

Authors:  Xinchun Zhou; Jinghe Mao; Junmei Ai; Youping Deng; Mary R Roth; Charles Pound; Jeffrey Henegar; Ruth Welti; Steven A Bigler
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.